Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase II Trial of Allovectin-7® for Metastatic Melanoma
NCT00044356 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
Conditions Studied
Interventions
- GENETIC Allovectin-7®
Study Locations (16)
California
- Comprehensive Blood and Cancer Center — Bakersfield
- University of California, San Francisco — San Francisco
Minnesota
- North Memorial Health Care — Robbinsdale
- Mayo Clinic — Rochester
Arizona
- Arizona Cancer Center — Tucson
Arkansas
- University of Arkansas Cancer Research Center — Little Rock
Colorado
- University of Colorado Cancer Center — Denver
Illinois
- Oncology Specialists, S.C. — Park Ridge
Louisiana
- Louisiana State University Medical Center — New Orleans
Maryland
- Hematology Oncology Associates of Baltimore — Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2001-02 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044356
The ClinicalTrials.gov registry entry for NCT00044356 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vical, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention — of which Allovectin-7® is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00044356 reports 16 study locations spanning 14 distinct geographic areas — top geographies include California, Minnesota, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00044356 about?
NCT00044356 is a clinical study titled "Phase II Trial of Allovectin-7® for Metastatic Melanoma". The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
What is the current status of trial NCT00044356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2001-02. Estimated completion is 2004-09.
What conditions does trial NCT00044356 study?
This clinical trial studies the following conditions: Melanoma, Metastatic Melanoma, Skin Cancer, Malignant Melanoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00044356?
The interventions under investigation include: Allovectin-7® (GENETIC). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00044356?
This trial is sponsored by Vical, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00044356 being conducted?
This trial has 16 study locations across Arizona, Arkansas, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.